Journal of Infection and Public Health, Journal Year: 2022, Volume and Issue: 15(11), P. 1234 - 1258
Published: Oct. 13, 2022
The recent Omicron (B.1.1.529) variant poses a significant threat to global health. This has spread worldwide, and several sublineages have rapidly emerged. Study tried analyze the microevolution of this variant.
Language: Английский
Cell Host & Microbe, Journal Year: 2022, Volume and Issue: 31(1), P. 9 - 17.e3
Published: Nov. 22, 2022
Language: Английский
Citations
241
bioRxiv (Cold Spring Harbor Laboratory), Journal Year: 2022, Volume and Issue: unknown
Published: Oct. 20, 2022
Abstract Continued evolution of SARS-CoV-2 has led to the emergence several new Omicron subvariants, including BQ.1, BQ. 1.1, BA.4.6, BF.7 and BA.2.75.2. Here we examine neutralization resistance these as well their ancestral BA.4/5, BA.2.75 D614G variants, against sera from 3-dose vaccinated health care workers, hospitalized BA.1-wave patients, BA.5-wave patients. We found enhanced in all especially BQ.1 BQ.1.1 subvariants driven by a key N460K mutation, lesser extent, R346T K444T mutations, BA.2.75.2 subvariant largely its F486S mutation. The also exhibited fusogenicity S processing dictated Interestingly, saw an enhancement mutation reduction D1199N processing, resulting minimal overall change. Molecular modelling revealed mechanisms receptor-binding non-receptor binding monoclonal antibody-mediated immune evasion R346T, K444T, mutations. Altogether, findings shed light on concerning newly emerging subvariants.
Language: Английский
Citations
80
Progress in Biophysics and Molecular Biology, Journal Year: 2023, Volume and Issue: 178, P. 32 - 49
Published: Feb. 20, 2023
Language: Английский
Citations
47
MedComm, Journal Year: 2023, Volume and Issue: 4(2)
Published: April 1, 2023
Coronavirus Disease-19 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome-coronaviruses-2 (SARS-CoV-2), a highly pathogenic and transmissible coronavirus. Most cases of COVID-19 have mild to moderate symptoms, including cough, fever, myalgias, headache. On the other hand, this coronavirus can lead complications death in some cases. Therefore, vaccination most effective tool prevent eradicate disease. Also, rapid diagnostic tests are critical identifying COVID-19. The pandemic has dynamic structure on agenda contains up-to-date developments. This article comprehensively discussed situation since it first appeared. For time, not only structure, replication mechanism, variants SARS-CoV-2 (Alpha, Beta, Gamma, Omicron, Delta, Epsilon, Kappa, Mu, Eta, Zeta, Theta, lota, Lambda) but also all details pandemic, such as how came out, spread, current cases, what precautions should be taken, prevention strategies, vaccines produced, developed, drugs used reviewed every aspect. Herein, comparison for terms procedure, accuracy, cost, time been presented. safety, efficacy, effectiveness against evaluated. Drug studies, therapeutic targets, various immunomodulators, antiviral molecules applied patients with reviewed.
Language: Английский
Citations
45
Science Immunology, Journal Year: 2022, Volume and Issue: 7(77)
Published: Sept. 20, 2022
BNT162b2-vaccinated individuals after Omicron BA.1 breakthrough infection have strong serum-neutralizing activity against BA.1, BA.2, and previous SARS-CoV-2 variants of concern (VOCs) yet less the highly contagious sublineages BA.4 BA.5 that displaced variants. Because latter are derived from we characterized COVID-19 mRNA vaccine triple-immunized who experienced BA.2 infection. We demonstrate sera these broadly neutralizing VOCs all tested sublineages, including BA.2-derived BA.2.12.1 BA.4/BA.5. Furthermore, applying antibody depletion, showed neutralization BA.4/BA.5 by convalescent is driven to a considerable extent antibodies targeting N-terminal domain (NTD) spike glycoprotein. However, depends exclusively on receptor binding (RBD). These findings suggest exposure in contrast glycoprotein, triggers substantial NTD-specific recall responses vaccinated thereby enhances sublineages. Given current epidemiology with predominance such as rapidly ongoing evolution, helped inform development our BA.4/BA.5-adapted vaccine.
Language: Английский
Citations
68
Nature Communications, Journal Year: 2022, Volume and Issue: 13(1)
Published: Oct. 12, 2022
Abstract Infection with SARS-CoV-2 variant Omicron is considered to be less severe than infection Delta, rarer occurrence of disease requiring intensive care. Little information available on comorbid factors, clinical conditions and specific viral mutational patterns associated the severity infection. In this multicenter prospective cohort study, patients consecutively admitted for COVID-19 in 20 care units France between December 7th 2021 May 1st 2022 were included. Among 259 patients, we show that phenotype infected ( n = 148) different from those Delta 111). We observe no significant relationship lineages/sublineages 28-day mortality (adjusted odds ratio [95% confidence interval] 0.68 [0.35–1.32]; p 0.253). Omicron-infected 43.2% are immunocompromised, most whom have received two doses vaccine or more (85.9%) but display a poor humoral response vaccination. The rate immunocompromised significantly higher non-immunocompromised (46.9% vs 26.2%; 0.009). Omicron, there association sublineages (BA.1/BA.1.1 109) BA.2 21)) any genome polymorphisms/mutational profile mortality.
Language: Английский
Citations
57
Cell Reports, Journal Year: 2023, Volume and Issue: 42(4), P. 112271 - 112271
Published: March 7, 2023
In November 2021, Omicron BA.1, containing a raft of new spike mutations, emerged and quickly spread globally. Intense selection pressure to escape the antibody response produced by vaccines or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection then led rapid succession sub-lineages with waves BA.2 BA.4/5 infection. Recently, many variants have such as BQ.1 XBB, which carry up 8 additional receptor-binding domain (RBD) amino acid substitutions compared BA.2. We describe panel 25 potent monoclonal antibodies (mAbs) generated from vaccinees suffering breakthrough infections. Epitope mapping shows mAb binding shifting 3 clusters, corresponding early-pandemic hotspots. The RBD mutations in recent map close these sites knock out severely down neutralization activity all but 1 mAb. This corresponds large falls titer vaccine BA.2, immune serum.
Language: Английский
Citations
38
British Journal of Haematology, Journal Year: 2023, Volume and Issue: 201(4), P. 628 - 639
Published: Feb. 20, 2023
Summary Outcome of early treatment COVID‐19 with antivirals or anti‐spike monoclonal antibodies (MABs) in patients haematological malignancies (HM) is unknown. A retrospective study HM treated for mild/moderate between March 2021 and July 2022 was performed. The main composite end‐point failure (severe COVID‐19‐related death). We included 328 consecutive who received MABs ( n = 120, 37%; sotrovimab, 73) 208, 63%; nirmatrelvir/ritonavir, 116) over a median two days after symptoms started; 111 (33.8%) had non‐Hodgkin lymphoma (NHL); 89 (27%) were transplant/CAR‐T (chimaeric antigen receptor T‐cell therapy) recipients. Most infections 309, 94%) occurred during the Omicron period. Failure developed 31 (9.5%). Its independent predictors older age, fewer vaccine doses, MABs. Rate lower versus pre‐Omicron period (7.8% 36.8%, p < 0.001). During period, doses diagnosis acute myeloid leukaemia/myelodysplastic syndrome (AML/MDS). Independent longer viral shedding comorbidities, hospital admission at diagnosis, NHL/CLL, COVID‐19‐associated mortality 3.4% 11). those severe 26% Patients significant risk treatment, even high rate.
Language: Английский
Citations
31
PLoS Pathogens, Journal Year: 2023, Volume and Issue: 19(4), P. e1010870 - e1010870
Published: April 20, 2023
Background The SARS-CoV-2 non-Spike (S) structural protein targets on nucleocapsid (N), membrane (M) and envelope (E), critical in the host cell interferon response memory T-cell immunity, are grossly overlooked COVID vaccine development. current Spike-only vaccines bear an intrinsic shortfall for promotion of a fuller T immunity. Vaccines designed to target conserved epitopes could elicit strong cellular immune responses that would synergize with B lead long-term success. We pursue universal (pan-SARS-CoV-2) against Delta, Omicrons ever-emergent new mutants. Methods findings explored booster immunogenicity UB-612, multitope-vaccine contains S1-RBD-sFc sequence-conserved promiscuous Th CTL epitope peptides Sarbecovirus N, M S2 proteins. To subpopulation (N = 1,478) infection-free participants (aged 18–85 years) involved two-dose Phase-2 trial, UB-612 (third dose) was administered 6–8 months after second dose. evaluated at 14 days post-booster overall safety monitored until end study. induced high viral-neutralizing antibodies live Wuhan WT (VNT 50 , 1,711) Delta 1,282); pseudovirus (pVNT 50, 11,167) vs. Omicron BA.1/BA.2/BA.5 variants 2,314/1,890/854), respectively. lower primary neutralizing elderly were uplifted upon boosting approximately same level young adults. also potent, durable Th1-oriented (IFN-γ + -) (peak/pre-boost/post-boost SFU/10 6 PBMCs, 374/261/444) along robust presence cytotoxic CD8 cells CD107a -Granzyme 3.6%/1.8%/1.8%). This vaccination is safe well tolerated without SAEs. Conclusions By targeting viral S2, N proteins, provide broad long-lasting B-cell immunity offers potential as fend off VoCs resorting Omicron-specific immunogens. Trial registration ClinicalTrials.gov ID: NCT04773067 ; NCT05293665 NCT05541861 .
Language: Английский
Citations
27
Nature Biomedical Engineering, Journal Year: 2023, Volume and Issue: 7(12), P. 1636 - 1648
Published: Sept. 21, 2023
Language: Английский
Citations
26